Centre Antoine Lacassagne-ko ikertzaileekin lankidetzan egindako argitalpenak (16)

2022

  1. Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers

    Communications biology, Vol. 5, Núm. 1, pp. 1061

2021

  1. 21-gene assay to inform chemotherapy benefit in node-positive breast cancer

    New England Journal of Medicine, Vol. 385, Núm. 25, pp. 2336-2347

  2. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

    Nature Communications, Vol. 12, Núm. 1

2020

  1. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

    Nature Genetics, Vol. 52, Núm. 1, pp. 56-73

2019

  1. The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

    npj Breast Cancer, Vol. 5, Núm. 1

2016

  1. Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

    Autophagy

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

    Autophagy, Vol. 12, Núm. 1, pp. 1-222

2015

  1. Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): A randomised, open-label, multicentre, phase 2 trial

    The Lancet Oncology, Vol. 16, Núm. 16, pp. 1700-1710

  2. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer

    New England Journal of Medicine, Vol. 372, Núm. 8, pp. 724-734

2014

  1. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: Investigation in the QUASAR2 study, systematic review, and meta-analysis

    Journal of Clinical Oncology, Vol. 32, Núm. 10, pp. 1031-1039

2013

  1. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): Overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

    The Lancet Oncology, Vol. 14, Núm. 6, pp. 461-471

2011

  1. Genitourinary Cancer

    INTRAOPERATIVE IRRADIATION: TECHNIQUES AND RESULTS, SECOND EDITION (HUMANA PRESS INC), pp. 459-479

2005

  1. Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005

    Annals of Oncology, Vol. 16, Núm. 10, pp. 1569-1583

2003

  1. Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines

    Annals of Oncology, Vol. 14, Núm. 8, pp. 1246-1252

2001

  1. Activity of Pemetrexed (ALIMTA®, multitargeted antifolate, LY231514) in metastatic breast cancer patients previously treated with an anthracycline and a taxane: An interim analysis

    Clinical Breast Cancer, Vol. 2, Núm. 1, pp. 47-51

1996

  1. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines

    Annals of Oncology, Vol. 7, Núm. 1, pp. 95-98